Skip to main content

Advertisement

SpringerLink
Log in

Increased dabigatran plasma concentration during Ibrutinib treatment: a case of cerebral hemorrhage and successful dabigatran reversal by idarucizumab

  • Case Report
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Byrd JC, Furman RR, Coutre SE et al (2015) Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125:2915

    Article  Google Scholar 

  2. Lipsky AH, Farooqui MZH, Tian X et al (2015) Incidence and risk factors of bleeding-related adverse in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 100:1571–1578

    Article  PubMed  PubMed Central  Google Scholar 

  3. Berglof A, Hamasy A, Meinke S et al (2015) Targets for Ibrutinib beyond B cell malignancies. Scand J Immunol 82:208–217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. McMullen JR, Boey EJH, Ooi JYY et al (2014) Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 124:3829–3830

    Article  CAS  PubMed  Google Scholar 

  5. Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy

    R. Quintavalla, M. Lombardi, C. Manotti, P. M. Ferrini, M. I. Tassoni & P. Rossetti

  2. Department of Cardiovascular Science Vascular Medicine Unit, University of Padua, Padua, Italy

    P. Prandoni

  3. Interventional Cardiology Unit, University Hospital of Parma, Parma, Italy

    I. Tadonio

  4. Hematology Unit and CTMO, University Hospital of Parma, Parma, Italy

    F. Re

  5. Department of Clinical and Experimental Medicine, University Hospital of Parma, Parma, Italy

    F. Quaini

Authors
  1. R. Quintavalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Prandoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Manotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Tadonio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Re
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. M. Ferrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. I. Tassoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Rossetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F. Quaini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Manotti.

Ethics declarations

Conflict of interest

Quintavalla R., Lombardi M., Prandoni P., Tadonio I., Re F. Tassoni M. I., Rossetti P., Quaini F., declare no conflict of interest. Manotti C., Ferrini P. M. had received a speaker honorarium from Boehringer Inghlheim.

Funding

This study not received any grant.

Ethical statement

All authors declare that to agree and give consent to submit the manuscript and to have read the ethical responsibility section of instructions for authors and agree with all rules reported for preserving the integrity of scientific record.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Quintavalla, R., Lombardi, M., Prandoni, P. et al. Increased dabigatran plasma concentration during Ibrutinib treatment: a case of cerebral hemorrhage and successful dabigatran reversal by idarucizumab. Aging Clin Exp Res 30, 93–95 (2018). https://doi.org/10.1007/s40520-017-0752-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40520-017-0752-5

Keywords

Search

Navigation